Effect of probucol in the treatment of familial hypercholesterolemia : an investigation of potential anti-inflammatory effects

Pao Yue-kong Library Electronic Theses Database

Effect of probucol in the treatment of familial hypercholesterolemia : an investigation of potential anti-inflammatory effects

 

Author: Wong, Chung Hang
Title: Effect of probucol in the treatment of familial hypercholesterolemia : an investigation of potential anti-inflammatory effects
Degree: M.Sc.
Year: 2016
Subject: Hypercholesteremia -- Treatment.
Phenols -- Therapeutic use.
Hong Kong Polytechnic University -- Dissertations
Department: Dept. of Health Technology and Informatics
Pages: xiv, 110 pages : color illustrations
Language: English
InnoPac Record: http://library.polyu.edu.hk/record=b2929086
URI: http://theses.lib.polyu.edu.hk/handle/200/8772
Abstract: Patient with familial hypercholesterolemia (FH) have marked increase in the risk of cardiovascular disease (CVD). Interleukin-6 (IL-6) and high sensitivity C-reactive protein (hsCRP) are sensitive and specific markers of inflammation, which is an important underlying factor in the development of atherosclerosis and CVD. The aim of this study was to investigate the potential anti-inflammatory effect of the drug probucol in the treatment of FH. Probucol has been suggested to have antioxidant and anti-inflamamtory effects and to offer potential benefit as an adjunct treatment to standard therapy of FH by statins. The study evaluated the effect of 24 weeks of probucol treatment on the plasma concentration of selected inflammatory markers (IL-6 and hs-CRP) in 20 FH patients on stable statin treatment. Fasting blood samples were collected at baseline, after 12 weeks and 24 weeks of probucol treatment, and IL-6 and hsCRP were measured using specific immunoassay methods. The results showed no significant differences between IL-6 (2.08 versus 2.12 pg/ml, p=0.983) or hsCRP (1.62 versus 2.99 mg/l, p=0.067) before and after 12-weeks of probucol treatment. Moreover, plasma IL-6(2.03 versus 1.73 pg/ml) and hsCRP (1.61 versus 2.17 mg/l) were not significantly different from baseline after 24 weeks of probucol treatment. In conclusion, up to 24 weeks probucol therapy had no significant effect on plasma IL-6 and hsCRP levels in these FH patients.

Files in this item

Files Size Format
b29290867.pdf 1.168Mb PDF
Copyright Undertaking
As a bona fide Library user, I declare that:
  1. I will abide by the rules and legal ordinances governing copyright regarding the use of the Database.
  2. I will use the Database for the purpose of my research or private study only and not for circulation or further reproduction or any other purpose.
  3. I agree to indemnify and hold the University harmless from and against any loss, damage, cost, liability or expenses arising from copyright infringement or unauthorized usage.
By downloading any item(s) listed above, you acknowledge that you have read and understood the copyright undertaking as stated above, and agree to be bound by all of its terms.

     

Quick Search

Browse

More Information